Clinical Analysis: 29-Year-Old Female with Post-Prandial Cough, Vomiting - PPI Non-Responder

The Clinical Picture

1. Laryngopharyngeal Reflux (LPR) / Atypical GERD - cough is a classic extra-esophageal manifestation; PPIs have notoriously poor response rates in LPR (~40-50%)
2. Functional Dyspepsia with GERD overlap - nausea/vomiting and postprandial symptoms suggest a motility component on top of acid
3. GERD with nocturnal acid breakthrough - PPIs fail to suppress nocturnal acid; a P-CAB addresses this gap

Drug 1: Fexuprazan (P-CAB - Potassium-Competitive Acid Blocker)

• Patient is a PPI non-responder
• Cough is a feature of LPR/atypical GERD - a 2024 RCT (Kim et al., PMID 39115573) showed fexuprazan 40 mg once daily improved hoarseness and troublesome cough faster than esomeprazole in severe LPR cases
• A 2025 RCT (Kang et al., PMID 40299084) showed fexuprazan 40 mg vs esomeprazole 40 mg for GERD-related chronic cough - both improved cough quality of life comparably, confirming fexuprazan as a valid PPI alternative for this specific symptom (74.3% of that study's patients were female, mean age 39 - very similar to this patient)
• Maintains intragastric pH ≥ 4 more effectively than esomeprazole, particularly overnight

Drug 2: Cinitapride (Prokinetic Agent)

• 5-HT4 (serotonin) receptor agonist - enhances acetylcholine release in the myenteric plexus, increasing LES tone, gastric emptying, and intestinal peristalsis
• 5-HT3 receptor antagonist - antiemetic effect
• D2 (dopamine) receptor antagonist (weak) - adds to prokinetic effect without the prominent CNS side effects seen with metoclopramide

• Vomiting and postprandial symptoms suggest a motility disorder component (delayed gastric emptying or impaired LES tone)
• GERD symptoms triggered by spicy meals + vomiting = likely gastroparesis-like delayed emptying keeping acid in contact with the LES longer
• Cinitapride accelerates gastric emptying, reduces postprandial reflux, and addresses nausea/vomiting directly
• Compared to cisapride (its predecessor), cinitapride at 1 mg TID has not been associated with cardiac arrhythmias - safer cardiac profile
• Not associated with significant CNS side effects unlike metoclopramide
• A 2025 real-world Chinese study (PMID 40332271) confirmed cinitapride is effective and well-tolerated in functional dyspepsia with overlapping GERD symptoms

Why the Combination Makes Sense

Why the Endoscopy Was Advised

• Baseline diagnosis before long-term acid suppression potentially masks findings
• Rule out erosive esophagitis (grade LA-A to D) - guides duration of therapy
• Rule out Barrett's esophagus - important in a young patient with chronic symptoms
• Exclude peptic ulcer disease (PUD), which can present with vomiting
• Detect H. pylori (biopsy/CLO test) - relevant since H. pylori can contribute to dyspepsia and PPI failure
• Rule out eosinophilic esophagitis - increasingly common in young females with atypical symptoms
• Confirm or refute structural vs. functional etiology before labeling as refractory GERD

Key Points Summary

• Fexuprazan replaces the failed PPI with a superior, rapid-onset, meal-timing-independent acid suppressor that handles nocturnal acid breakthrough and atypical GERD cough
• Cinitapride addresses the motility arm - vomiting, delayed gastric emptying, LES competence - without the CNS risks of metoclopramide
• The combination addresses both the acid and motility components of a likely mixed acid-motility GERD/LPR presentation
• Endoscopy at 1 week is appropriate to establish a structural diagnosis before long-term treatment

• PMID 40299084 - Fexuprazan vs esomeprazole for GERD-related chronic cough (RCT, 2025) - confirms fexuprazan equivalence for PPI in cough management
• PMID 39115573 - Fexuprazan in laryngopharyngeal reflux (RCT, 2024) - shows faster cough and hoarseness improvement with fexuprazan in severe LPR
• PMID 40332271 - Cinitapride in functional dyspepsia with GERD overlap (2025 real-world study) - confirms efficacy and tolerability

Three Questions Answered: Normal Endoscopy, FibroScan, and H. pylori

1. Why Was the Endoscopy Normal? What Does "Functional" Mean?

• Functional Dyspepsia (FD) - postprandial distress syndrome subtype (symptoms triggered by meals, nausea, vomiting, no organic lesion)
• Laryngopharyngeal Reflux (LPR) with functional component - cough from reflux without visible esophageal damage
• H. pylori-associated gastritis - endoscopy can look grossly normal even when H. pylori is present; biopsy is needed to confirm histologic gastritis, but the doctor found H. pylori likely through a rapid urease test (CLO test) done during the scope, or breath test/stool antigen

2. Why FibroScan of the Liver After 1 Week?

The H. pylori - Liver Connection

What the Evidence Says

• H. pylori-positive patients had 17% higher risk of developing NAFLD (RR = 1.17, 95% CI 1.10-1.24)
• NAFLD patients had 13% higher rate of H. pylori positivity (RR = 1.13, 95% CI 1.02-1.24)

• Fasting blood glucose and HbA1c
• Triglycerides and BMI
• Liver steatosis scores (measured by FibroScan's CAP parameter)
• Inflammatory markers (IL-6, TNF-α, hs-CRP)

What the FibroScan Actually Measures

1. Liver stiffness (kPa) - detects fibrosis (scarring) - higher stiffness = more fibrosis
2. Controlled Attenuation Parameter / CAP (dB/m) - detects steatosis (fat) - higher CAP = more fat

Why 1 Week Timing?

• Baseline the liver before H. pylori eradication treatment begins to alter it
• Assess whether liver steatosis/fibrosis is already present - which would change long-term management
• Check if the unexplained GI symptoms partly reflect hepatic involvement (fatty liver can cause right upper quadrant discomfort, nausea, early satiety)
• Guide metabolic workup (lipid profile, insulin resistance, blood glucose) if NAFLD is found

3. Is H. pylori a Normal Bacteria? Is It Found Normally in the Gut?

The Reality

• H. pylori is a pathogen, classified as a Group 1 carcinogen by the WHO/IARC since 1994
• It colonizes the stomach specifically (not the rest of the gut) by surviving the acidic environment using specialized mechanisms
• It is not commensal - meaning it provides no benefit to the host, and its presence always causes some degree of histologic gastritis even if symptoms are absent

How It Survives in the Stomach

1. Urease enzyme - converts urea into ammonia, creating a local neutralizing cloud around itself
2. Acid-inhibitory protein - directly suppresses acid secretion near the bacteria
3. Spiral shape + flagella - burrows through and under the mucus layer to reach epithelial cells where pH is less hostile
4. Surface adhesins - sticks to gastric epithelial cells tightly
5. CagA and VacA virulence proteins - injects toxins into epithelial cells to establish permanent colonization and evade immune clearance

Why Does It Seem "Common"?

• 70-90% of people in developing countries are colonized, most before age 10 (via fecal-oral route, often within families)
• ~40% prevalence in developed countries
• But prevalence does not equal normal - it simply reflects widespread exposure in settings with poor sanitation/hygiene

• Almost all develop histologic gastritis (infiltration of neutrophils into the gastric mucosa)
• 10-15% develop peptic ulcer disease
• 1-3% eventually develop gastric adenocarcinoma
• <1% develop gastric MALT lymphoma

One Interesting Nuance

Summary of the Clinical Picture

• PMID 39161913 - 34-study meta-analysis: H. pylori + NAFLD bidirectional link (2024)
• PMID 36376474 - RCT: H. pylori eradication improves liver steatosis on FibroScan (2022)
• PMID 35410853 - Systematic review + meta-analysis confirming H. pylori as NAFLD risk factor (2022)

Upper GI Endoscopy - Full Interpretation & Evidence-Based Next Steps

Endoscopy Findings - Structured Interpretation

Finding 1: Mild Antral Gastritis + Positive RUT

• H. pylori preferentially colonizes the antrum (the lower stomach), where it triggers neutrophil-predominant inflammation visible as erythema
• The RUT works because H. pylori urease converts urea in the biopsy/swab to ammonia, which turns the pH indicator pink/red - a positive result confirms live, metabolically active infection
• This explains her symptoms entirely: nausea, postprandial vomiting, cough (from acid reflux driven by gastritis), PPI non-response (H. pylori-driven inflammation reduces PPI efficacy and H. pylori itself is known to alter gastric acid secretion)

Finding 2: Esophageal Prominent Veins - WHY THE FIBROSCAN

1. NAFLD/MASLD with early portal hypertension - the most likely here given the H. pylori connection (as discussed previously - H. pylori → insulin resistance → hepatic steatosis → portal hypertension)
2. Non-cirrhotic portal hypertension - extrahepatic portal vein obstruction, portal vein thrombosis
3. Chronic hepatitis B or C - undiagnosed viral hepatitis causing early fibrosis
4. Autoimmune hepatitis - more common in young females
5. Wilson's disease - genetic copper storage disease presenting in young adults

• FibroScan uses transient elastography to measure liver stiffness (kPa) - detects fibrosis - and CAP (dB/m) - detects steatosis
• The prominent esophageal veins suggest portal hypertension may already be present
• FibroScan will quantify whether liver fibrosis/steatosis is the cause
• If FibroScan is abnormal → further workup (Doppler ultrasound of portal vein, LFTs, viral hepatitis serology, autoimmune markers, ceruloplasmin)

Evidence-Based Next Steps (Tiered Approach)

Step 1: H. pylori Eradication (CURRENTLY STARTED - Optimize)

"We advise against PPI-clarithromycin triple therapy. PCAB-based regimens are preferred over PPI-based regimens where available."

• Fexuprazan 40 mg + Clarithromycin 500 mg + Amoxicillin 1g - all twice daily x 14 days

• Fexuprazan/PPI + Bismuth + Tetracycline + Metronidazole x 14 days

Step 2: FibroScan (PLANNED - Confirm and Act on Results)

Step 3: Parallel Bloodwork to Order Now

• LFTs (AST, ALT, GGT, ALP, bilirubin, albumin) - assess baseline liver function
• CBC with platelets - thrombocytopenia is an early sign of portal hypertension
• Coagulation profile (PT/INR) - liver synthetic function marker
• HBsAg, Anti-HBc, Anti-HCV - rule out viral hepatitis
• ANA, ASMA, Anti-LKM1 - autoimmune hepatitis screen (young female!)
• Ceruloplasmin + serum copper - Wilson's disease (presents in young adults with liver disease)
• Fasting glucose + HbA1c + fasting lipids - metabolic syndrome / NAFLD workup
• TSH - thyroid dysfunction can cause fatty liver

Step 4: Confirm H. pylori Eradication

• Urea Breath Test (UBT) or Stool Antigen Test at minimum 4 weeks after completing antibiotics
• Patient must be off PPI/P-CAB for 2 weeks before testing (can use H2 blocker as bridge)
• Do not re-scope unless symptoms persist after confirmed eradication

Step 5: Long-Term Follow-Up

• If NAFLD confirmed on FibroScan - lifestyle modification (diet + exercise) + treat metabolic risk factors
• H. pylori eradication itself has been shown to reduce liver steatosis (RCT evidence, Yu et al. 2022, PMID 36376474) - treating the infection may directly improve the liver
• Repeat upper GI endoscopy in 2-3 years to reassess esophageal vein prominence after liver status is clarified
• If prominent veins persist or worsen → portal pressure measurement / hepatology-guided management

Summary Visual

Endoscopy Results
       ↓
┌──────────────────────┬───────────────────────────┐
│ Antral Erythema      │ Prominent Esophageal Veins│
│ + Positive RUT       │                           │
│        ↓             │         ↓                 │
│ H. pylori Gastritis  │  Portal hypertension?     │
│ → Eradication Tx     │  Early varices?           │
│   (P-CAB based)      │         ↓                 │
│                      │   FibroScan + Doppler US  │
│                      │   + Liver bloodwork       │
└──────────────────────┴───────────────────────────┘
              ↓
    H. pylori eradication also
    reduces hepatic steatosis
    (addresses both problems)

• PMID 38577188 - P-CAB triple therapy superior to PPI triple therapy for H. pylori (meta-analysis, 2024)
• PMID 36376474 - H. pylori eradication reduces liver steatosis on FibroScan (RCT, 2022)
• PMID 39161913 - H. pylori-NAFLD bidirectional link, 175,575 patients (meta-analysis, 2024)
• 2024 ACG H. pylori Treatment Guidelines - favor P-CAB and bismuth-based regimens, confirm eradication at 4 weeks post-therapy